Marvin 07271014562D 26 28 0 0 0 0 999 V2000 10.2161 -3.9636 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.3400 -4.6443 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 11.2995 -5.9340 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.0649 -4.5806 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.2189 -2.6140 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 12.4371 -6.6230 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 13.5612 -5.9896 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.0513 -5.8868 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 7.9272 -3.8916 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 6.7542 -5.8591 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 6.7896 -4.5170 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 7.9000 -6.5345 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 5.5837 -6.5385 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 10.1753 -6.5675 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 12.3965 -7.9128 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 5.5809 -7.8573 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.1075 -7.8715 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.2587 -8.5687 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 13.5672 -4.6596 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 15.8367 -4.6280 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 14.6966 -3.9946 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 15.8367 -5.9896 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 16.9713 -3.9630 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 14.6966 -2.6646 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 16.9713 -2.6330 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 15.8155 -1.9996 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 0 0 0 3 2 1 0 0 0 0 4 1 1 0 0 0 0 5 1 2 0 0 0 0 6 3 1 0 0 0 0 7 6 1 0 0 0 0 8 4 1 0 0 0 0 9 4 2 0 0 0 0 10 11 2 0 0 0 0 11 9 1 0 0 0 0 12 8 2 0 0 0 0 13 10 1 0 0 0 0 14 3 2 0 0 0 0 15 6 2 0 0 0 0 16 13 1 0 0 0 0 17 14 1 0 0 0 0 18 17 2 0 0 0 0 12 10 1 0 0 0 0 18 15 1 0 0 0 0 7 19 1 0 0 0 0 20 21 1 0 0 0 0 21 19 1 0 0 0 0 22 20 1 0 0 0 0 23 20 1 0 0 0 0 24 21 1 0 0 0 0 25 26 1 0 0 0 0 26 24 1 0 0 0 0 25 23 1 0 0 0 0 M END > CHEBI:4788 > encainide > 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market. > 3 > CHEBI:239046 > Encainide; 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide; 4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide; (+-)-4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide; (+-)-2'-[2-(1-methyl-2-piperidyl)ethyl]-p-anisanilide > 4-methoxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide > encainidum; encainide; encainide; encainida > C22H28N2O2 > 352.46990 > 352.21508 > 0 > COc1ccc(cc1)C(=O)Nc1ccccc1CCC1CCCCN1C > InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25) > PJWPNDMDCLXCOM-UHFFFAOYSA-N > 497572 > 66778-36-7 > 66778-36-7 > DB01228 > C06978 > D07894 $$$$